Objective:To investigate the efficacy of Ezetimibe combined with Rosuvastatin in patients with acute coronary syndrome (ACS).Method:A total of 156 patients with ACS treated in the First People's Hospital of Zhaoqing from October 2021 to August 2023 were selected and divided into two groups according to random number table method,with 78 cases in each group.The control group was treated with Rosuvastatin,and the observation group was additionally treated with Ezetimibe.The levels of serum blood lipid four items and hypersensitive C reactive protein (hs-CRP) were compared between the two groups,and the adverse reactions were recorded.Result:After 6 weeks and 3 and 12 months of treatment,triglyceride,low-density lipoprotein cholesterol,total cholesterol and hs-CRP in observation group were lower than those in control group,and high-density lipoprotein cholesterol were higher than those in control group,the differences were statistically significant (P<0.05).There were no significant differences in the incidences of adverse reactions between the two groups after 6 weeks and 3 and 12 months of treatment (P>0.05).Conclusion:Combined use of Ezetimibe and Rosuvastatin can better improve blood lipids of ACS patients and reduce the level of hs-CRP,with good safety.
关键词
急性冠脉综合征/依折麦布/瑞舒伐他汀/血脂四项/超敏C反应蛋白
Key words
Acute coronary syndrome/Ezetimibe/Rosuvastatin/Blood lipid four items/Hypersensitive C reactive protein
维普
万方数据